ELTXElicio Therapeutics, Inc.

ELTX Stock Price, Valuation & Chart | Elicio Therapeutics, Inc.

Compare

$2.550-0.01 (-0.39%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology ELTX intrinsic value ELTX calculated fair value vs price

Overview Financials Dividends Ratios

ELTX Historical price chart

ELTX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization48.62M

PE Ratio-1.18

EPS-2.17

Trading Volume395.84K

Today's High/Low2.6/2.48

Dividend Yield0.00

52 Week High/Low16.0/2.48

Shares Outstanding19.07M

ELTX Financial Statement

ELTX Analyst ratings

ELTX Analysis & performance metrics

ELTX Company profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.…

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a…

ELTX Management team

Name

Position

Robert T. ConnellyCEO

Chief Executive Officer, President & Director

Allen Richard Nissenson F.A.S.N., FACP, M.D.CTO

Founder & Independent Director

Joy Seymour

Vice President & Head of Regulatory Affairs

Peter DeMuth Ph.D.

Chief Scientific Officer

Christopher M. Haqq M.D., Ph.D.

Executive Vice President, Head of Research & Development and Chief Medical Officer

Preetam Shah M.B.A., Ph.D.

Chief Strategy & Financial Officer and Treasurer

Thian Kheoh Ph.D.

Senior Vice President of Biometrics

Esther Welkowsky

Senior Vice President of Clinical Development

Name

Position

Robert T. ConnellyCEO

Chief Executive Officer, President & Director

Allen Richard Nissenson F.A.S.N., FACP, M.D.CTO

Founder & Independent Director

Joy Seymour

Vice President & Head of Regulatory Affairs

Peter DeMuth Ph.D.

Chief Scientific Officer

Christopher M. Haqq M.D., Ph.D.

Executive Vice President, Head of Research & Development and Chief Medical Officer

Preetam Shah M.B.A., Ph.D.

Chief Strategy & Financial Officer and Treasurer

Thian Kheoh Ph.D.

Senior Vice President of Biometrics

Esther Welkowsky

Senior Vice President of Clinical Development

Management Team

Robert T. ConnellyCEO

Chief Executive Officer, President & Director

Allen Richard Nissenson F.A.S.N., FACP, M.D.CTO

Founder & Independent Director

Joy Seymour

Vice President & Head of Regulatory Affairs

Peter DeMuth Ph.D.

Chief Scientific Officer

Christopher M. Haqq M.D., Ph.D.

Executive Vice President, Head of Research & Development and Chief Medical Officer

Preetam Shah M.B.A., Ph.D.

Chief Strategy & Financial Officer and Treasurer

Thian Kheoh Ph.D.

Senior Vice President of Biometrics

Esther Welkowsky

Senior Vice President of Clinical Development

Management

Robert T. ConnellyCEO

Chief Executive Officer, President & Director

Allen Richard Nissenson F.A.S.N., FACP, M.D.CTO

Founder & Independent Director

Joy Seymour

Vice President & Head of Regulatory Affairs

Peter DeMuth Ph.D.

Chief Scientific Officer

Christopher M. Haqq M.D., Ph.D.

Executive Vice President, Head of Research & Development and Chief Medical Officer

Preetam Shah M.B.A., Ph.D.

Chief Strategy & Financial Officer and Treasurer

Thian Kheoh Ph.D.

Senior Vice President of Biometrics

Esther Welkowsky

Senior Vice President of Clinical Development

Total 8 executives

ELTX Frequently asked questions

What is Elicio Therapeutics, Inc. (ELTX) Stock Price?

Current stock price of Elicio Therapeutics, Inc. (ELTX) stock is $2.550. The stock price is -0.39% lower in the session. The intraday range can be seen from this page. Volume of Elicio Therapeutics, Inc. (ELTX) stock is 395.84K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Elicio Therapeutics, Inc. (ELTX) stock price going up or down today?

The stock price of Elicio Therapeutics, Inc. (ELTX) can change with earnings, company news, and overall market sentiment. Elicio Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Elicio Therapeutics, Inc. stock expensive at its current price?

Whether Elicio Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ELTX on this page is -1.18. EPS on this page is -2.17. Compare those figures with peers and growth expectations before deciding if the current Elicio Therapeutics, Inc. price is justified.

How has the stock price of Elicio Therapeutics, Inc. (ELTX) performed historically?

Historical performance for Elicio Therapeutics, Inc. (ELTX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ELTX reacted to past earnings and market events.

Should I buy Elicio Therapeutics, Inc. (ELTX) stock, at this price?

Buying Elicio Therapeutics, Inc. (ELTX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.